Aclara Biosciences (NASDAQ:ACLA)
Historical Stock Chart
From Jun 2019 to Jun 2024
![Click Here for more Aclara Biosciences Charts. Click Here for more Aclara Biosciences Charts.](/p.php?pid=staticchart&s=N%5EACLA&p=8&t=15)
ACLARA and Cell Signaling Technology, Inc. Enter into Antibody Supply Agreement
MOUNTAIN VIEW, Calif. and BEVERLY, Mass., Dec. 4 /PRNewswire-FirstCall/ --
ACLARA BioSciences, Inc. and Cell Signaling Technology, Inc. (CST), today
announced the signing of a supply and license agreement, for the use and resale
by ACLARA of certain CST reagents in conjunction with ACLARA's eTag(TM) Assay
System. These reagents include phospho-specific antibodies to key signaling
molecules such as kinases and related materials. CST has expertise in the
generation and commercialization of these types of reagents, and has built a
strong reputation for quality products.
Signal transduction pathways, and the molecules that comprise them, chiefly
kinases, have been an important focus for cell biology research for many years.
The significant role they play in directing such critical processes as cell
differentiation, proliferation and death is now moving them to the forefront of
pharmaceutical discovery. For instance, the U.S. Food and Drug Administration
has approved two kinase inhibitors for use in certain types of cancer:
Gleevec(TM) from Novartis and Iressa(R) from AstraZeneca.
"We believe that, aided by highly specific antibodies such as those from CST,
ACLARA's multiplexed, multi-label eTag Assay System will play an important role
in the characterization of signal transduction pathways in cells and tissues,
and the development of novel medicines targeting these pathways," stated Michael
Dunn, ACLARA's chief business officer. The eTag system permits precise and
reproducible quantification of the activation state of kinases and other
phosphoproteins in complex biological samples, information that is very
important to researchers probing cellular pathways."
"Cell Signaling Technology is very excited about ACLARA's eTag technology as an
important discovery application for our antibodies," said Christopher Bunker,
CST's director of business development. "CST's antibodies provide superior
content that enable the unique types of cellular analysis only possible with the
eTag platform, and we anticipate that this technology will be critical in
advancing research toward targeted therapeutics."
About the eTag Assay System
The eTag Assay System is a high performance, high throughput system for the
simultaneous measurement of 10's to 100's of genes, proteins, and cell-based
antigens across thousands of samples. The eTag platform makes it possible for
researchers to measure multiple aspects of a complex biological system, enabling
the study of gene expression, protein expression, cell signaling and pathway
activation, protein-protein interaction, post-translational modifications and
cell receptor binding -- all in the same sample and with the same platform. The
system uses ACLARA's proprietary eTag reporters to multiplex the analysis of
genes and/or proteins. Specific molecular binding events result in the release
of electrophoretically distinct eTag reporters, which are then resolved by
standard capillary electrophoresis to provide precise, sensitive quantitation of
multiple analytes -- directly from cell lysates of cultured or primary cells, as
well as fresh and fixed tissue samples.
ACLARA's eTag Assay System is being commercialized for use both in drug
discovery research and to support preclinical and clinical development of
specific targeted therapies. These programs allow scientists to utilize eTag
reagent products, software, and services. For multiplexed gene expression,
ACLARA uses eTag Multiplex Invader(R) Assays, which incorporate Invader
technology and Cleavase(R) enzyme and are licensed for use from Third Wave
Technologies, Inc.
About ACLARA
ACLARA BioSciences, Inc. is developing advanced tools for drug discovery and
development using its proprietary eTag assay platform. The Company's products
provide researchers with decision-critical information for drug development,
which previously was difficult or impossible to obtain. The solution-phase eTag
Assay System is cost-effective, easy-to-use and flexible, and enables highly
accurate, precise and sensitive analysis of genes and/or proteins from limited
amounts of biological samples. Importantly, researchers can use their existing
instrument platforms to perform eTag analyses. More information on ACLARA can be
obtained on the Company's web site at http://www.aclara.com/.
About Cell Signaling Technology
Cell Signaling Technology, Inc. has expertise and the market leadership position
in the development and commercialization of phospho-specific antibodies for
kinase and pathway activation measurement. CST's phospho-specific antibodies
are validated on an array of cellular and biochemical assay platforms and are
critical reagents used in basic biomedical research, pharmaceutical drug
discovery, and clinical pathology. More information on CST can be obtained at
the Company's web site at http://www.cellsignal.com/
Forward Looking Statement
All statements in this news release that are not historical are forward-looking
statements within the meaning of the Securities Exchange Act of 1934 as amended.
Such forward-looking statements are subject to factors that could cause actual
results to differ materially for ACLARA from those projected. Those factors
include risks and uncertainties relating to the performance of the Company's
products, product development, development and commercialization efforts,
successful establishment of and performance under collaborative and commercial
agreements, adoption of its technologies by pharmaceutical and biotechnology
companies, the validity and enforceability of patents, the possible infringement
of the intellectual property of others, technological approaches of ACLARA and
its competitors, and other risk factors identified in the Company's Form 10-K
for the year ended December 31, 2002 and Form 10-Q for the quarter ended
September 30, 2003 as filed with the Securities and Exchange Commission.
Trademarks
ACLARA BioSciences, eTag, and the ACLARA logo are trademarks of ACLARA
BioSciences, Inc. Invader and Cleavase are registered trademarks of Third Wave
Technologies, Inc. Gleevec and Iressa are trademarks of Novartis and
AstraZeneca, respectively.
DATASOURCE: ACLARA BioSciences, Inc.
CONTACT: Alfred Merriweather, VP, Finance and CFO of ACLARA BioSciences,
Inc., +1-650-210-1200, or
Web site: http://www.cellsignal.com/
Web site: http://www.aclara.com/